Phase 4 Completed N=608 Treatment

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes

Source: ClinicalTrials.gov NCT00833027 ↗

Enrolled (actual)

608

Serious AEs

2.8%

Results posted

Sep 2010

Primary outcomePrimary: Change From Baseline in HbA1c at Week 24 — -0.6 Percent — p=<0.001

Summary

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in HbA1c at Week 24	-0.6	<0.001 sig
SECONDARY Change From Baseline in HbA1c at Week 12	-0.6	—

Eligibility Criteria

Inclusion Criteria

Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00833027). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.